Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

▪ Specific scoring systems developed for patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) (Garc'a-Manero G et al. Leukemia 2008; Falantes J et al. Clin Lymphoma Myeloma Leuk 2013) are able to identify a significant fraction of pts with a poorer (median OS, 13 months) than expec...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2013-11, Vol.122 (21), p.2754-2754
Main Authors: Falantes, Jose F, Delgado, Regina García, Calderón, Cristina, Valcarcel, David, Montoro, Julia, De Miguel, Dunia, Márquez-Malaver, Francisco J, Bailen, Alicia, Bargay, Joan, Bernal, Teresa, Gonzalez-Porras, Jose R, Tormo, Mar, Ramos, Fernando, Andreu, Rafael, Xicoy, Blanca, Nomdedeu, Benet, Brunet, Salut, Sanchez, Joaquin, Jurado, Antonio Fernández, Bonanad, Santiago, Espigado, Ildefonso, Pérez-Simón, Jose Antonio, Sanz, Guillermo
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:▪ Specific scoring systems developed for patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) (Garc'a-Manero G et al. Leukemia 2008; Falantes J et al. Clin Lymphoma Myeloma Leuk 2013) are able to identify a significant fraction of pts with a poorer (median OS, 13 months) than expected outcome (Greenberg P et al. Blood 1997). Retrospective data of azacitidine (AZA) in LR-MDS showed hematological improvement and survival when compared to non-responder pts (Lyons R et al. J Clin Oncol 2009; Musto P et al. Cancer 2010). However, the impact of AZA treatment in the group of LR-MDS with poor prognosis by a LR-specific score (LR-S) is uncertain. To evaluate the impact of AZA treatment in LR-MDS pts with more adverse LR-S by multivariable time-dependent analysis. Eighty-eight LR-MDS pts (IPSS Low/Int-1 or
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V122.21.2754.2754